DocMorris Q1 Revenue Jumps 10.7% on Strong Rx Sales

Key Q1 Financial Highlights

DocMorris AG (SIX:DOCM) announced a strong start to the year, with first-quarter revenue reaching CHF 318.1 million. This represents a 10.7% increase in local currency. The company also demonstrated significant progress in profitability, with its adjusted EBITDA loss narrowing by nearly CHF 10 million year-over-year.

Performance Overview

The primary driver of growth was the prescription drug segment, where German Rx sales surged by 26.4% year-over-year to CHF 68.1 million. Non-prescription sales also showed positive momentum, growing 6.5% in local currency. Notably, the digital services division, which includes TeleClinic and marketplace operations, expanded by 63.1%. The active user base grew by 3.3% from the previous quarter to 12.6 million users.

Financial Outlook and Market Impact

DocMorris reported an adjusted EBITDA of negative CHF 6.3 million, a substantial improvement from the prior year. For the full year, the company projects revenue growth in the mid-single-digit to low-teens range and aims for an adjusted EBITDA between negative CHF 10 million and negative CHF 25 million. Management has set a clear target to achieve EBITDA break-even by the fourth quarter and free cash flow break-even in 2027. These positive financial developments and a clear path toward profitability are likely to be viewed favorably by the market.

Summary

DocMorris's first-quarter results underscore robust growth in its core segments and a significant improvement in its financial health. The company's strategic focus on expanding its prescription drug business and digital services is yielding positive results, positioning it on a clear trajectory towards achieving its profitability milestones.

FAQ

Q: What was DocMorris's total revenue in Q1?
A: DocMorris reported Q1 revenue of CHF 318.1 million, marking a 10.7% growth in local currency.

Q: Which segment drove the most growth for DocMorris?
A: The prescription drug segment showed notable momentum with German Rx sales up 26.4%, while the digital services segment grew by 63.1%.

Q: What are DocMorris's profitability goals?
A: The company aims to achieve EBITDA break-even by the fourth quarter of this year and free cash flow break-even in 2027.

Source: Investing.com